Fig 1.
*The patients excluded for protocol violation were judged non-adherent to the induction regimen prescribed.
Table 1.
Demographic and clinical characteristics of the patients at study entry.
Fig 2.
Upper panel. Kaplan-Meier estimate of the time from the start of treatment to remission of the patients who were later assigned to receive cyclophosphamide (CYC) or methotrexate (MTX). Lower panel. Kaplan-Meier estimate of the time from remission to first relapse or death (during the planned 24 month-follow-up) in the cyclophosphamide (CYC) and methotrexate (MTX) groups.
Table 2.
Relapse frequencies during the planned 24-month follow-up period.
Table 3.
Adverse events during the planned 24-month follow-up period.
Fig 3.
Subgroup analysis of the Kaplan-Meier estimate of the time from remission to first relapse or death (during the planned 24 month-follow-up) in the cyclophosphamide (CYC) and methotrexate (MTX) groups.
The upper panel shows the analysis in patients with GPA or MPA (granulomatosis with polyangiitis or microscopic polyangiitis) while the lower panel shows the analysis in patients with EGPA (eosinophilic granulomatosis with polyangiitis).